Lv3
300 积分 2023-09-04 加入
Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome
1个月前
已完结
A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma
1个月前
已完结
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
5个月前
已完结
GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial
7个月前
已关闭
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
8个月前
已完结
Engineered T cell therapy for hepatocellular carcinoma: the dawn of precision immunotherapy?
8个月前
已完结
Implications of T cell receptor biology on the development of new T cell therapies for cancer
8个月前
已完结
Epigenetic agents plus anti-PD-1 reshapes tumor microenvironment and restores antitumor efficacy in Hodgkin lymphoma
9个月前
已完结
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
9个月前
已完结
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study
9个月前
已完结
皖公网安备34019202002308
